Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Enzyme Inhibition01:30

Enzyme Inhibition

89.8K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
89.8K
Enzymes02:34

Enzymes

91.4K
Inside living organisms, enzymes act as catalysts for many biochemical reactions involved in cellular metabolism. The role of enzymes is to reduce the activation energies of biochemical reactions by forming complexes with its substrates. The lowering of activation energies favor an increase in the rates of biochemical reactions.
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
91.4K
Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

2.4K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of a Quinolone-Based Scaffold as a Dual SARS-COV-2 PLᵖʳᵒ and Mᵖʳᵒ Inhibitor: An Integrated Molecular Modeling and In-vitro Evaluation Approach.

Drug design, development and therapy·2026
Same author

Identification of Putative Equilibrative Nucleoside Transporter Inhibitors Through Dual-Pharmacophore Virtual Screening and Validation in a Gemcitabine-Based Cell Assay.

Molecules (Basel, Switzerland)·2026
Same author

Prediction of Charged Small Molecule Conformations in Solution Using a Balanced ML/MM Potential.

Journal of chemical information and modeling·2026
Same author

The Discovery of Small ERK5 Inhibitors via Structure-Based Virtual Screening, Biological Evaluation and MD Simulations.

Molecules (Basel, Switzerland)·2025
Same author

Curcumin Derivatives as Allosteric Modulator of α7-nAChR: Functional and Molecular Docking Insights.

Medical principles and practice : international journal of the Kuwait University, Health Science Centre·2025
Same author

FibrilGen: A Python Package for Atomistic Modeling of Peptide β-Sheet Nanostructures.

Journal of chemical information and modeling·2025

Related Experiment Video

Updated: Dec 15, 2025

Monitoring Protein Aggregation Kinetics In Vivo using Automated Inclusion Counting in Caenorhabditis elegans
06:49

Monitoring Protein Aggregation Kinetics In Vivo using Automated Inclusion Counting in Caenorhabditis elegans

Published on: December 17, 2021

3.2K

How Do Small Molecule Aggregates Inhibit Enzyme Activity? A Molecular Dynamics Study.

Mohammad A Ghattas1, Sara Al Rawashdeh2, Noor Atatreh1

  • 1College of Pharmacy, Al Ain University, Abu Dhabi, United Arab Emirates.

Journal of Chemical Information and Modeling
|July 7, 2020
PubMed
Summary
This summary is machine-generated.

Small molecule drug aggregates can cause false positives in drug discovery assays. Molecular dynamics simulations reveal these miconazole aggregates non-specifically inhibit enzymes like beta-lactamase and PTP1B by blocking active sites.

More Related Videos

Characterizing Individual Protein Aggregates by Infrared Nanospectroscopy and Atomic Force Microscopy
12:58

Characterizing Individual Protein Aggregates by Infrared Nanospectroscopy and Atomic Force Microscopy

Published on: September 12, 2019

10.2K
NMR-Based Activity Assays for Determining Compound Inhibition, IC50 Values, Artifactual Activity, and Whole-Cell Activity of Nucleoside Ribohydrolases
10:24

NMR-Based Activity Assays for Determining Compound Inhibition, IC50 Values, Artifactual Activity, and Whole-Cell Activity of Nucleoside Ribohydrolases

Published on: June 30, 2019

10.4K

Related Experiment Videos

Last Updated: Dec 15, 2025

Monitoring Protein Aggregation Kinetics In Vivo using Automated Inclusion Counting in Caenorhabditis elegans
06:49

Monitoring Protein Aggregation Kinetics In Vivo using Automated Inclusion Counting in Caenorhabditis elegans

Published on: December 17, 2021

3.2K
Characterizing Individual Protein Aggregates by Infrared Nanospectroscopy and Atomic Force Microscopy
12:58

Characterizing Individual Protein Aggregates by Infrared Nanospectroscopy and Atomic Force Microscopy

Published on: September 12, 2019

10.2K
NMR-Based Activity Assays for Determining Compound Inhibition, IC50 Values, Artifactual Activity, and Whole-Cell Activity of Nucleoside Ribohydrolases
10:24

NMR-Based Activity Assays for Determining Compound Inhibition, IC50 Values, Artifactual Activity, and Whole-Cell Activity of Nucleoside Ribohydrolases

Published on: June 30, 2019

10.4K

Area of Science:

  • Biochemistry
  • Computational Chemistry
  • Drug Discovery

Background:

  • Small molecule compounds forming colloidal aggregates in solution pose challenges in early drug discovery.
  • Protein adsorption onto these aggregates can lead to false positive results in inhibition assays.

Purpose of the Study:

  • To investigate the molecular mechanisms behind non-specific protein inhibition by small molecule aggregates.
  • To explore the interaction between miconazole aggregates and target proteins (beta-lactamase, PTP1B) using molecular dynamics simulations.

Main Methods:

  • Utilizing molecular dynamics (MD) simulations to model protein-aggregate interactions in aqueous solution.
  • Analyzing the adsorption of beta-lactamase and PTP1B onto pre-formed miconazole aggregates.

Main Results:

  • MD simulations confirmed the formation of miconazole aggregates and their subsequent association with beta-lactamase and PTP1B.
  • Simulations showed persistent occlusion of protein active sites by miconazole molecules within the aggregates.
  • Protein tertiary structure and dynamics remained largely unchanged on the microsecond timescale, indicating non-specific binding.

Conclusions:

  • Miconazole aggregates act as nonspecific inhibitory agents due to their heterogeneous surface polarity.
  • Protein active site occlusion by aggregates occurs through surficial interactions or protein envelopment.
  • Understanding these protein-aggregate interactions is crucial for drug design, drug delivery, and analytical biochemistry.